TrustCore Financial Services’s CRISPR Therapeutics CRSP Stock Holding History

TrustCore Financial Services’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$406	Hold	10	–	–	﹤0.01%	976
2022 Q3	$1K	Hold	10	–	–	﹤0.01%	993
2022 Q2	$1K	Hold	10	–	–	﹤0.01%	978
2022 Q1	$1K	Hold	10	–	–	﹤0.01%	987
2021 Q4	$1K	Sell	10 -300	-97%	-$26.2K	﹤0.01%	902
2021 Q3	$35K	Hold	310	–	–	﹤0.01%	544
2021 Q2	$50K	Hold	310	–	–	0.01%	456
2021 Q1	$38K	Buy	310 +110	+55%	+$16.6K	﹤0.01%	485
2020 Q4	$31K	Buy	+200	New	+$23.6K	﹤0.01%	486

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

TrustCore Financial Services's CRSP Position: Q4 2022 in Review

TrustCore Financial Services held its CRISPR Therapeutics (CRSP) position steady in Q4 2022 at 10 shares worth $406. The position accounts for ﹤0.01% of the portfolio, ranked #976.

TrustCore Financial Services first reported a position in CRSP in Q4 2020 and has held it in 9 quarters since. The position peaked at $50K in Q2 2021. 398 funds tracked by Wall St. Rank hold CRSP as of Q4 2022.

TrustCore Financial Services held 10 shares of CRISPR Therapeutics worth $406 as of Q4 2022.
TrustCore Financial Services left its CRISPR Therapeutics share count unchanged in Q4 2022.
CRISPR Therapeutics made up ﹤0.01% of TrustCore Financial Services's portfolio in Q4 2022, its #976 holding.
TrustCore Financial Services first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 9 quarters since.
TrustCore Financial Services's CRISPR Therapeutics position peaked at $50K in Q2 2021.
398 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2022.

Based on TrustCore Financial Services's 13F filing for Q4 2022, filed 13 Feb 2023.